home / stock / kmpr / kmpr articles
MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE:PFLT) today announced that PennantPark Seni...
Although U.S. stocks closed higher on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence...
At least three people are reported to have died on Tuesday, Feb. 6 as a result of the floods and mudslides that swept across Southern California. U...
JOSEPH LACHER JR, President and CEO at Kemper (NYSE:KMPR), reported a large insider buy on November 28, according to a new SEC filing. What Happen...
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidenc...
HSBC raised the price target for Constellation Brands, Inc. (NYSE: STZ) from $280 to $290. HSBC analyst Carlos Laboy maintained a Buy rating. Co...
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 127.8% to $0.1269. The company recently reported second-quarter results. AERWINS Technolo...
U.S. stocks traded higher, with the Dow Jones falling around 180 points on Friday. Here are some big stocks recording losses in today’s sessi...
News, Short Squeeze, Breakout and More Instantly...
The Kemper Foundation announced that the Read Conmigo bilingual educator grant applications are now open for the fall 2024 grant cycle. The Read Conmigo program focuses on advancing bilingual literacy in Hispanic and Latino communities, and enables educators to provide rich, engaging learni...
Kemper Corporation (NYSE: KMPR) reported net income of $71.3 million, or $1.10 per diluted share, for the first quarter of 2024, compared to a net loss of $80.1 million, or $(1.25) per share, for the first quarter of 2023. Adjusted Consolidated Net Operating Income 1 was $69.7 million, or...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...